Latest news with #Pauls
Yahoo
7 days ago
- Entertainment
- Yahoo
USA Sled Hockey Team honored at Bisons game
BUFFALO, N.Y. (WIVB) — The USA Sled Hockey Team was honored at Tuesday night's Bisons game against the Charlotte Knights after winning 4-3 against Czechia in the World Para Ice Hockey Championships earlier in the day. Team USA defenseman and four-time Paralympic gold medalist Josh Pauls threw the first pitch of the game. Pauls has the most gold medals of any sled hockey player and also holds the title of being a six-time world champion. Advertisement Team USA will play China in the semifinals on Friday. Latest Local News Katie Skoog joined the News 4 team in April 2024. She is a graduate from the University at Buffalo. You can view more of her work here. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed. For the latest news, weather, sports, and streaming video, head to News 4 Buffalo.
Business Wire
27-05-2025
- Business
- Business Wire
Savara Receives Refusal to File (RTF) Letter From the U.S. Food and Drug Administration (FDA) for the Biologics License Application (BLA) for MOLBREEVI* to Treat Patients With Autoimmune Pulmonary Alveolar Proteinosis (autoimmune PAP)
LANGHORNE, Pa.--(BUSINESS WIRE)-- Savara Inc. (Nasdaq: SVRA) (the Company), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, today announced that the Company received an RTF letter from the FDA for the BLA of MOLBREEVI as a therapy to treat patients with autoimmune PAP. Upon preliminary review, the FDA determined that the BLA submitted in March 2025 was not sufficiently complete to permit substantive review and requested additional data related to Chemistry, Manufacturing, and Controls (CMC). The RTF was not the result of safety concerns, and the FDA did not request or recommend additional efficacy studies. Within the next 30 days, the Company intends to request a Type A meeting with the Agency. Typically, Type A meetings are granted by the FDA within 30 days of the request. 'The requested CMC data outlined in the RTF letter are currently being generated, and we look forward to meeting with the FDA to align on next steps,' said Matt Pauls, Chair and Chief Executive Officer, Savara. 'Based on our understanding of the letter, we are confident we can thoroughly address the Agency's request and expect to resubmit our BLA in the fourth quarter of 2025. We remain highly confident in our program for autoimmune PAP and believe that our clinical data demonstrate that MOLBREEVI improves pulmonary gas transfer and respiratory health-related quality of life in this rare disease.' Pauls continued, 'As outlined in our Annual Report, we are working to establish a redundant supply chain. Pursuant to that strategy, we remain on track to complete the technology transfer with our second-source drug substance contract manufacturer in the fall. We have completed three upstream process performance qualification (PPQ) batches, are in the process of completing our downstream PPQ campaign and have begun our analytical comparability analysis.' The RTF does not impact previous designations granted by regulators for MOLBREEVI in autoimmune PAP. MOLBREEVI in autoimmune PAP has been granted Fast Track and Breakthrough Therapy Designations by the FDA, Orphan Drug Designation by the FDA and the European Medicines Agency (EMA), as well as Innovation Passport (IP) and Promising Innovative Medicine (PIM) designations by the UK's Medicines and Healthcare Products Regulatory Agency (MHRA). Autoimmune PAP is a rare lung disease characterized by the abnormal build-up of surfactant in the alveoli of the lungs. Surfactant consists of proteins and lipids and is an important physiological substance that lines the alveoli to prevent them from collapsing. In a healthy lung, excess surfactant is cleared and digested by immune cells called alveolar macrophages. Alveolar macrophages need to be stimulated by granulocyte-macrophage colony-stimulating factor (GM-CSF) to function properly in clearing surfactant, but in autoimmune PAP, GM-CSF is neutralized by antibodies against GM-CSF, rendering macrophages unable to adequately clear surfactant. As a result, an excess of surfactant accumulates in the alveoli, causing impaired gas exchange, resulting in clinical symptoms of shortness of breath, often with cough and frequent fatigue. Patients may also experience episodes of fever, chest pain, or coughing up blood, especially if secondary lung infection develops. In the long term, the disease can lead to serious complications, including lung fibrosis and the need for a lung transplant. Savara is a clinical-stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, MOLBREEVI*, is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (autoimmune PAP). MOLBREEVI is delivered via an investigational eFlow ® Nebulizer System (PARI Pharma GmbH) specifically developed for inhalation of a large molecule. Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at and LinkedIn. *MOLBREEVI is the FDA and EMA conditionally accepted trade name for molgramostim inhalation solution. It is not approved in any indication. MOLBREEVI is a trademark of Savara Inc. Forward-Looking Statements Savara cautions you that statements in this press release that are not a description of historical fact are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words referencing future events or circumstances such as 'expect,' 'intend,' 'plan,' 'anticipate,' 'believe,' and 'will,' among others. Such statements include, but are not limited to, statements related to the Company's intention to request a Type A meeting with the FDA, our confidence in our ability to thoroughly address the Agency's request, our expectations regarding the resubmission of the BLA and the timing of the resubmission, our belief that our clinical data demonstrate that MOLBREEVI improves pulmonary gas transfer and respiratory health-related quality of life in autoimmune PAP, and that we remain on track to complete the technology transfer with our second-source contract manufacturer in the fall. Savara may not actually achieve any of the matters referred to in such forward-looking statements, and you should not place undue reliance on these forward-looking statements. These forward-looking statements are based upon Savara's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, the risks associated with our ability to successfully develop, obtain regulatory approval for, and commercialize MOLBREEVI for autoimmune PAP; the occurrence and outcome of the planned Type A meeting with the FDA; our ability to address the FDA's request and successfully meet the requirements for resubmission; our ability to project future cash utilization and reserves needed for contingent future liabilities and business operations; the availability of sufficient resources for Savara's operations and to conduct or continue planned clinical development programs; and the timing and ability of Savara to raise additional capital as needed to fund continued operations. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. For a detailed description of our risks and uncertainties, you are encouraged to review our documents filed with the SEC including our recent filings on Form 8-K, Form 10-K, and Form 10-Q. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Savara undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law.
Yahoo
27-05-2025
- Business
- Yahoo
Savara Receives Refusal to File (RTF) Letter From the U.S. Food and Drug Administration (FDA) for the Biologics License Application (BLA) for MOLBREEVI* to Treat Patients With Autoimmune Pulmonary Alveolar Proteinosis (autoimmune PAP)
LANGHORNE, Pa., May 27, 2025--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, today announced that the Company received an RTF letter from the FDA for the BLA of MOLBREEVI as a therapy to treat patients with autoimmune PAP. Upon preliminary review, the FDA determined that the BLA submitted in March 2025 was not sufficiently complete to permit substantive review and requested additional data related to Chemistry, Manufacturing, and Controls (CMC). The RTF was not the result of safety concerns, and the FDA did not request or recommend additional efficacy studies. Within the next 30 days, the Company intends to request a Type A meeting with the Agency. Typically, Type A meetings are granted by the FDA within 30 days of the request. "The requested CMC data outlined in the RTF letter are currently being generated, and we look forward to meeting with the FDA to align on next steps," said Matt Pauls, Chair and Chief Executive Officer, Savara. "Based on our understanding of the letter, we are confident we can thoroughly address the Agency's request and expect to resubmit our BLA in the fourth quarter of 2025. We remain highly confident in our program for autoimmune PAP and believe that our clinical data demonstrate that MOLBREEVI improves pulmonary gas transfer and respiratory health-related quality of life in this rare disease." Pauls continued, "As outlined in our Annual Report, we are working to establish a redundant supply chain. Pursuant to that strategy, we remain on track to complete the technology transfer with our second-source drug substance contract manufacturer in the fall. We have completed three upstream process performance qualification (PPQ) batches, are in the process of completing our downstream PPQ campaign and have begun our analytical comparability analysis." The RTF does not impact previous designations granted by regulators for MOLBREEVI in autoimmune PAP. MOLBREEVI in autoimmune PAP has been granted Fast Track and Breakthrough Therapy Designations by the FDA, Orphan Drug Designation by the FDA and the European Medicines Agency (EMA), as well as Innovation Passport (IP) and Promising Innovative Medicine (PIM) designations by the UK's Medicines and Healthcare Products Regulatory Agency (MHRA). About Autoimmune Pulmonary Alveolar Proteinosis (autoimmune PAP) Autoimmune PAP is a rare lung disease characterized by the abnormal build-up of surfactant in the alveoli of the lungs. Surfactant consists of proteins and lipids and is an important physiological substance that lines the alveoli to prevent them from collapsing. In a healthy lung, excess surfactant is cleared and digested by immune cells called alveolar macrophages. Alveolar macrophages need to be stimulated by granulocyte-macrophage colony-stimulating factor (GM-CSF) to function properly in clearing surfactant, but in autoimmune PAP, GM-CSF is neutralized by antibodies against GM-CSF, rendering macrophages unable to adequately clear surfactant. As a result, an excess of surfactant accumulates in the alveoli, causing impaired gas exchange, resulting in clinical symptoms of shortness of breath, often with cough and frequent fatigue. Patients may also experience episodes of fever, chest pain, or coughing up blood, especially if secondary lung infection develops. In the long term, the disease can lead to serious complications, including lung fibrosis and the need for a lung transplant. About Savara Savara is a clinical-stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, MOLBREEVI*, is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (autoimmune PAP). MOLBREEVI is delivered via an investigational eFlow® Nebulizer System (PARI Pharma GmbH) specifically developed for inhalation of a large molecule. Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at and LinkedIn. *MOLBREEVI is the FDA and EMA conditionally accepted trade name for molgramostim inhalation solution. It is not approved in any indication. MOLBREEVI is a trademark of Savara Inc. Forward-Looking Statements Savara cautions you that statements in this press release that are not a description of historical fact are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words referencing future events or circumstances such as "expect," "intend," "plan," "anticipate," "believe," and "will," among others. Such statements include, but are not limited to, statements related to the Company's intention to request a Type A meeting with the FDA, our confidence in our ability to thoroughly address the Agency's request, our expectations regarding the resubmission of the BLA and the timing of the resubmission, our belief that our clinical data demonstrate that MOLBREEVI improves pulmonary gas transfer and respiratory health-related quality of life in autoimmune PAP, and that we remain on track to complete the technology transfer with our second-source contract manufacturer in the fall. Savara may not actually achieve any of the matters referred to in such forward-looking statements, and you should not place undue reliance on these forward-looking statements. These forward-looking statements are based upon Savara's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, the risks associated with our ability to successfully develop, obtain regulatory approval for, and commercialize MOLBREEVI for autoimmune PAP; the occurrence and outcome of the planned Type A meeting with the FDA; our ability to address the FDA's request and successfully meet the requirements for resubmission; our ability to project future cash utilization and reserves needed for contingent future liabilities and business operations; the availability of sufficient resources for Savara's operations and to conduct or continue planned clinical development programs; and the timing and ability of Savara to raise additional capital as needed to fund continued operations. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. For a detailed description of our risks and uncertainties, you are encouraged to review our documents filed with the SEC including our recent filings on Form 8-K, Form 10-K, and Form 10-Q. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Savara undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law. View source version on Contacts Media and Investor Relations Contact Savara Johnson, Executive Director, Corporate Affairsir@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
15-05-2025
- Business
- Yahoo
Q1 2025 DiaMedica Therapeutics Inc Earnings Call
Operator Good morning, ladies and gentlemen, and welcome to the DiaMedica Therapeutics first quarter 2025 conference call. An audio recording of the webcast will be available shortly after the call today on DiaMedica's website at in the investor relations section. Before DiaMedica proceeds with its remarks, please note that the company will be making forward-looking statements on today's call. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected in these statements. More information, including factors that could cause actual results to differ from projected results, appears in the section entitled Cautionary Note regarding forward-looking statements. In the company's press release issued yesterday and under the heading Risk factors in the company's most recent annual report on Form 10K and most recent quarterly report, Form 10Q. DiaMedica's SEC filings are available on the SEC's website and on its website Please also note that any comments made on today's call speak only as of today, May 14, 2025 and may no longer be accurate at the time of any replay or transcript re-reading. DiaMedica disclaims any duty to update its forward-looking statements. Following the prepared remarks, the phone lines will be open for questions. I would now like to turn you over to your host for today's call, Mr. Rick Pauls, DiaMedica's President and Chief Executive Officer. Mr. Pauls. Thank you, operator. Hello, everyone, and welcome to our first quarter 2025 conference call. I am joined this morning by Scott Kellen, our Chief Financial Officer Dr. Lorianne Masuokais currently on short-term medical leave, and we hope she gets well soon. We're happy to be here today to update you on the progress on our two clinical development programs. It has only been a short interval since our last update. That's I'll keep my remarks brief. That said, I'm pleased to report that we continue to make substantial progress in both of our clinical development programs. I'll start with an update on a Preeclampsia program. Building upon the significant accomplishments of this program within a very short time frame as we discussed in March, we're pleased to be able to disclose that we believe Part 1A of our phase 2 investigative sponsored preeclampsia trial is very close to identifying a target dose to move forward with it in Part 1 B. Dose selection will be guided primarily a few key data points which we expect to be sharing in our upcoming preliminary top line results from the part 1A proof of concept portion of the trial. These key data points include 1, safety and tolerability, including results of a placental transfer analysis. 2. the amount of decrease in systolic and diastolic blood pressure levels and 3. changes in uterine and placental blood flow as assessed by the Doppler ultrasound measurement of the uterine artery pulsatility index. This measure is important as reductions in the pulsatility index may suggest decreased downstream resistance and improved uterine and placental blood flow, which could also be an indication of disease modifying. Currently we expect to be in a position to release those preliminary topline results between the 2nd half of June and the 1st half of July. The final timing will be primarily dependent on the schedules at the outside laboratories running the various tests, including the pharmacodynamic biomarkers and the assay, which will be used to determine if DM 189 crosses the placental barrier. One additional update May is preeclampsia Awareness Month, and we will be sponsoring a preeclampsia key opinion leader call on May 28th at 8 a.m. Eastern. Compared to other therapeutic areas like oncology, which have advanced more rapidly in recent years, the treatment of pregnancy complications remains outdated and is not well understood. No FDA approved treatments exist for preeclampsia despite the growing burden of this disease. To our knowledge, DM 19 is the only novel agent currently being studied in pregnant women with preeclampsia. With this KOL events, we will continue our work to educate investors, physicians, and other interested parties on preeclampsia as a disease and the current state of treatment. With this background, we will also discuss the design of our current phase 2 trial of DM-189 in preeclampsia. Turning briefly to our stroke program, enrollment is moving ahead steadily, and we're pleased to announce that participant enrollment now is between the 20th and 25th percentile mark of patients enrolled for the interim analysis. Our next enrollment update will be at the 50th percentile mark. We believe that our efforts over the past year to engage with sites to promote communications between the sites and to simplify study logistics have been important in driving the recent uptick in enrollment. Accordingly, we reiterated our guidance that the interim analysis on those 1st 200 participants will be completed in the first half of 2026. I would also note for you that we have engaged an experienced stroke neurologist to support site engagement during Lorianne's leave in order to maintain our enrollment momentum in the Remedy II trial. This individual has spent over 10 years treating stroke patients at a major US research center and also has 5 years of recent biotech drug development experience. He has been doing a tremendous job connecting with and maintaining our relationships with sites and supporting our recent enrollment momentum. Now, I'd like to hand the call over to Scott Kellen to review this quarter's financial results. Thanks, Rick, and good morning everyone. As the operator mentioned, we announced our first quarter, 2025 financial results and filed our quarterly report on Form 10Q yesterday after the markets closed. These documents are both available on either the DiaMedica or the SEC websites. As of March 31, 2025, we reported a total combined cash and investments of $37.3 million. Current liabilities of $4.7 million and working capital of $32.8 million. This compares to a total combined cash and investments of $44.1 million, $5.4 million in current liabilities, and $39.2 million in working capital as of December 31, 2024. The decreases in combined cash and investments and in working capital were due primarily to the net cash used to fund our operations. The net cash used in operating activities for the first quarter of 2025 was $7.1 million compared to $6.7 million for the first quarter of 2024. The increase in cash used in operating activities resulted primarily from our increased net loss, partially offset by changes in operating assets abilities occurring during the current year period. We anticipate that our current cash and investments provides us a runway into Q3 of 2026. Our research and development expenses increased to $5.7 million for the three months ended March 31, 2025, up from $3.7 million for the three months ended March 31, 2024. The increase was due primarily to cost increases resulting from the continuation of our remedy to clinical trial, including our global expansion, increased manufacturing development activity, and the expansion of our clinical team during 2024. Now these increases were partially offset by cost reductions related to in use study work performed and completed in the prior year period. We expect that our R&D expenses will moderately increase in future periods relative to our recent prior periods as we continue our remedy to trial, including the global expansion and our continued expansion of our DM 199 clinical development program in preeclampsia. Our general and administrative expenses were $2.5 million and $2.1 million for the three months ended March 31, 2025, and 2024 respectively. This increase resulted primarily from additional non-cash share-based compensation expense recognized as a result of the approval of an extension of the post-termination exercise period for stock options held by a retiring member of our board of directors. We expect G&A expenses to remain steady in future periods as compared to recent prior periods. Our net other income was $443,000 for the three months ended March 31, 2025, compared to $597,000 for the three months ended in March 31, 2024. This decrease was driven by reduced interest income recognized during the current year period related to lower average marketable securities balances during the current year period as compared to the prior year period. With that, let me ask the operator to open the lines for questions. Operator Thank you so much, ladies and gentlemen. We'll now begin our question and answer session. Should you have a question, please press star, followed by one on your touchtone phone. You will hear a prompt that your hand has been raised. Should you wish to remove your hand from the queue, please press star, followed by 2. If you're using a speakerphone, please lift the handset before pressing any keys. One moment for your first question. And your first question comes from Thomas Flatton with Lake Street. Please go ahead. Good morning. I appreciate you taking the questions. Hey, Rick, just to clarify, the laboratory test results that seem to be the variable in terms of the readout between June and July, is that primarily the test for DM 199 crossing the placental barrier, so in the umbilical cord, or is there something else there that we should be aware of? Yeah, Thomas, yeah, absolutely. So that's the main item is going to be the placental transfer. So we have an essay that we're just having finalized in terms of getting to lower limits of detection. And so it's just a question of time for them to run it. So we want to at least give a range today in terms of when we anticipate the results. Makes sense. And then, I see you mentioned that you're expecting to start part 1 B in Q3. What are the triggers for part 2 and 3, so the expected management and the fetal growth restriction components of the study? So, I'll start off with the fetal growth restrictions. So, if we see dilation of the intrauterine arteries, our investigators are prepared to move ahead with that cohort, and then we'll have more to talk about the part two when we delight the results here in the coming weeks. Got it. Excellent I appreciate. You taking the questions. Thank you. Thanks, Thomas. Operator Your next question comes from Matthew Caufield with HC Wainwright. Please go ahead. Hi, good morning, guys. Thanks for taking our question. I was wondering if you could speak to the anticipated read through or any de-risking between the initial preeclampsia data and how that profile could translate to AIS development and the remedy to trial. Thanks again. Sure, I mean, I'll start off by saying that these are definitely two very unique indications, but I will add that a positive effect here in preeclampsia will just be another confirmation that this protein is active. And I would also mention around that we've previously talked about the fact that there are two forms of this protein in Asia that are being used. So, the formula protein isolated from human urine that today is treating close to a million patients per year for acute ischemic stroke, and then it's also a form of protein isolated from pig pancreas in both Japan and China. And we've been able to track down about 10 publications with that form of the protein to treat preeclampsia. So I think it'll just be very encouraged and you know that we have an active protein and what we're seeing in some of the validation and rationale for going into both of these indications is what we'll call the crude forms in Asia today. Thanks a lot appreciate it guys. Thank you. Operator Your next question comes from Chase Knickerbocker with Craig Hallam. Please go ahead. Good morning. Thanks for taking the questions. Rick, just on stroke, be good to kind of get some incremental details on enrollment. I mean, maybe just kind of starting out with those high volume or potential high-volume centers, can you kind of give us an update on what percentage of kind of those high-volume accounts are now, at that 1 to 2 per month that you want to see? I would add that, as we had kind of talked on past calls, we really do, we really did think that there would be a small number of sites, in particularly in the US that would drive enrollment, and as we're starting to build some momentum, that's clearly what we're starting to see. So some of these high enrolling sites are seeing the 1 to 2 patients per site per month and so. We're working on building momentum and then really working hard on some of those other sites to expand the relationship here to encourage, but, I say currently we are above our plan here now and you know we're encouraged with the with the momentum that's being built. So maybe just an update on overall centers as well as, again, it's only been a couple of months here, but, we have we expanded that past 30 and then maybe on the geographic footprint of those centers that we started to see some international enrollment coming in. Yeah, so we're currently in mid-30s, and keeping in mind that there are sites now that are not performing that we're shutting down and so we're really again focusing on the high-end rolling sites. We also have sites in Georgia that have been performing very well. And that's where that is the country of Georgia. Yeah, I got it, and just kind of I guess summing all this up, first half 26 interim analysis, I think at least implies that, enrollment rates continue to pick up, and I mean you're seeing that trajectory in, recent weeks, recent months as far as that curve continuing to steepen. Yeah, absolutely, and from the last earnings call, we're definitely seeing an encouraging uptick. Got it, that's it for me. Thanks. Great, thanks, Chase. Operator Your next question comes from Thomas Flatten with Lake Street. Please go ahead. Yeah, hey, thanks for taking another question. Just back to preeclampsia real quick, the part 2 and 3, those are, those studies will be primarily based out of South Africa, or are you thinking that there's going to be a US component to those which would necessitate ID filing? So that part 2 and part 3 are still part of the same protocol, and so our collaborators will not need to go back for regulatory clearance. And at some point, will you expand the study and if so, when into the US? We do plan in the future to expand this to the US and global, and you know we'll have more to share at a later date. Right now, the focus is getting the part 1A and then moving into the part 1B as well as parts2 and then 3 hopefully. Got it. I appreciate it. Thank you. Yes, thanks, Thomas. Operator Thank you. There are no further questions at this time. I would like to turn the call back to Mr. Rick Pauls. Alright, in closing, we're very encouraged by our steady progress and clear momentum across both the preeclampsia and stroke programs. We look forward to sharing upcoming key milestones, including the top line results from our preeclampsia approve a concept trial and the interim analysis from our stroke program. We thank our dedicated team. Investigators and importantly our patients and their families for the continued trust and commitment. Please also mark your calendars from May 28th at 8 a.m. Eastern time for our preeclampsia KOL event. We'll be sending out the call in details via press release early next week. As always, we appreciate the ongoing support of our shareholders and look forward to updating you further in the months ahead. Thank you again for joining our call today. This concludes our call. Operator Ladies and gentlemen, you may now disconnect. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Chicago Tribune
06-05-2025
- Sport
- Chicago Tribune
Taking advantage of an opportunity, Bella Pauls comes through for Andrew. Winning mindset? ‘Be here for the team.'
Senior Bella Pauls is a pitcher for Andrew, but not on a regular basis. She plays in the outfield, but on more or less an as-needed basis. Pauls is not an everyday player for the Thunderbolts. But she is a wonderful example of a kid that you want on your team. Her dedication is MVP-worthy. 'Even when I am sitting on the bench, I want to be here for the team,' Pauls said. 'This team is so much fun. Coach (Alyssa) Gunther really helps out with that and makes it nice to be here.' The Concordia Wisconsin recruit was given a big chance to pitch Monday. And Pauls came up aces for host Andrew in a 4-3 SouthWest Suburban Conference win in nine innings over Lincoln-Way West in Tinley Park. Texas recruit MaTaia Lawson had four hits for Andrew (14-8, 5-4). Emma Scislowicz walked it off on an infield smash that drove in courtesy runner Aubrey Shewmaker. Addy Ridgway added two hits for the Thunderbolts. Reese Forsythe, Reese Rourke and Molly Finn each finished with two hits for Lincoln-Way West (16-8, 5-5). Lawson was the hitting hero of the day with a two-out triple that tied the game in the bottom of the seventh inning. She also had a double during the game-deciding rally in the ninth. 'I take it as just another at-bat and try to do my job,' Lawson said. 'You just have to have confidence. When it goes through, it feels great.' For Pauls, it was a day to feel exceptionally great. The right-hander went all nine innings, striking out eight. She stranded six baserunners, keeping the Thunderbolts within striking distance. 'It meant so much to me to be able to start today,' Pauls said. 'We've had a rocky last couple of weeks, but I came in with a lot of confidence in my defense. I knew they would try their best and we got the job done.' Pauls earned the quality start for a couple of reasons. 'She's been throwing a lot of strikes of late,' Gunther said. 'She has been making competitive pitches. When she has to come into a game, she has been doing her job. 'Bella also works really hard at practice. It's hard to not be an everyday starter, but she trusted the process and stuck with it. It was fun watching her throw a lot of strikes out there in this game.' Pauls threw a bevy of them in the top of the ninth. She struck out the side, catching the final batter looking. 'That was definitely my best inning,' Pauls said, her eyes lighting up. 'I wanted to make my team proud.' Pauls is in her second season on the varsity. She's one of three pitchers with Carleton recruit Clare Hester and Kerra O'Reilly. Monday's win boosted Pauls' pitching record to 4-0. She has 34 strikeouts in 43 1/3 innings. Her role on the varsity has been different from her time as a regular on the freshman and JV teams. 'It can be tough, but I've always looked up to Clare and I'm glad to have her,' Pauls said. 'I also looked to my college coaches a lot for advice. I came to practice and worked my hardest and just took things one day at a time' Scislowicz can vouch for the work ethic. 'Oh, Bella never gives up,' Scislowicz said. 'She does so much extra stuff. Some people might sit and say, 'I can't do anything else.' But she is out there 24/7, trying to get better. 'Watching her out there today, she was definitely tired, but she kept pushing and pushing. She goes all out. She's the best.'
